Compare HROW & CDNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HROW | CDNA |
|---|---|---|
| Founded | 1998 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical Specialities |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 1.5B |
| IPO Year | 2008 | 2007 |
| Metric | HROW | CDNA |
|---|---|---|
| Price | $39.48 | $46.38 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 8 | 6 |
| Target Price | ★ $69.86 | $28.00 |
| AVG Volume (30 Days) | 550.4K | ★ 1.1M |
| Earning Date | 05-11-2026 | 04-28-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 71.43 | N/A |
| EPS | N/A | ★ 2.13 |
| Revenue | N/A | ★ $48,324,000.00 |
| Revenue This Year | $31.62 | $16.01 |
| Revenue Next Year | $50.77 | $11.31 |
| P/E Ratio | ★ N/A | $21.28 |
| Revenue Growth | N/A | ★ 18.93 |
| 52 Week Low | $28.54 | $11.27 |
| 52 Week High | $54.98 | $49.76 |
| Indicator | HROW | CDNA |
|---|---|---|
| Relative Strength Index (RSI) | 49.09 | 68.03 |
| Support Level | $37.03 | $16.70 |
| Resistance Level | $41.82 | $49.76 |
| Average True Range (ATR) | 1.80 | 2.23 |
| MACD | -0.00 | -0.21 |
| Stochastic Oscillator | 49.15 | 78.10 |
Harrow Inc is an eyecare pharmaceutical company engaged in the discovery, development, and commercialization of ophthalmic pharmaceutical products for the U.S. market. The company partners with U.S. eyecare professionals to develop products used to manage ophthalmic conditions affecting both the front and back of the eye, such as dry eye disease, cataracts, refractive errors, glaucoma, etc. Its portfolio of branded ophthalmic pharmaceuticals includes Iheezo, Vevye, Byooviz Opuviz, Natacyn, Maxitrol, Maxidex, etc. Additionally, the company's development pipeline comprises candidates like MELT-300, H-N08, CR-01, and MELT-210, being developed to address unmet needs in eye care and selected adjacent markets. Its reportable segments are: Branded, which derives maximum revenue, and ImprimisRx.
CareDx Inc operates as a precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. It offers testing services, products, and digital solutions along with the pre- and post-transplant patient journey and is a provider of genomics-based information for transplant patients. The Company's commercially available testing services consist of AlloSure Kidney, AlloMap Heart, AlloSure Heart, a dd-cfDNA solution for heart transplant patients, and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. Geographically it generates the majority of its revenue from the United States. The company generates the majority of revenue from the Testing services.